Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety

Pharmacoeconomics. 2017 Dec;35(12):1297-1310. doi: 10.1007/s40273-017-0587-0.


Background: The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications.

Objective: The objective of this study was to estimate the cost effectiveness of implementing a novel pharmacogenomic test (IDgenetix®) to guide treatment choices in patients with depression and/or anxiety compared with treatment as usual from the US societal perspective.

Methods: We developed a discrete event simulation to compare clinical events, quality-adjusted life-years, and costs of the two treatment strategies. Target patients had a Hamilton Rating Scale for Depression Score ≥ 20 and/or a Hamilton Rating Scale for Anxiety score ≥ 18 at baseline. Remission, response, and no response were simulated based on the observed rates in the IDgenetix® randomized controlled trial. Quality-adjusted life-years and direct and indirect costs attributable to depression and anxiety were estimated and compared over a 3-year time horizon. We conducted extensive deterministic and probabilistic sensitivity analyses to assess the robustness of the results.

Results: The model predicted cumulative remission rates of 78 and 66% in IDgenetix® and treatment as usual groups, respectively. Estimated discounted quality-adjusted life-years were 2.09 and 1.94 per patient for IDgenetix® and treatment as usual, respectively, which resulted in 0.15 incremental quality-adjusted life-years (95% credible interval 0.04-0.28). The total costs after accounting for a US$2000 test cost were US$14,124 for IDgenetix® compared with US$14,659 for treatment as usual, suggesting a US$535 (95% credible interval - 2902 to 1692) cost saving per patient in the IDgenetix® group. Incremental quality-adjusted life-year gain (0.49) and cost savings (US$6800) were substantially larger in patients with severe depression (Hamilton Rating Scale for Depression score ≥ 25).

Conclusion: Using the IDgenetix® test to guide the treatment of patients with depression and anxiety may be a dominant strategy, as it improves quality-adjusted life-years and decreases overall costs over a 3-year time horizon.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Anxiety / drug therapy*
  • Anxiety / economics
  • Anxiety / genetics
  • Computer Simulation
  • Cost Savings
  • Cost-Benefit Analysis
  • Depression / drug therapy*
  • Depression / economics
  • Depression / genetics
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pharmacogenetics / economics
  • Pharmacogenetics / methods*
  • Pharmacogenomic Testing / economics
  • Pharmacogenomic Testing / methods*
  • Psychiatric Status Rating Scales
  • Quality-Adjusted Life Years
  • Randomized Controlled Trials as Topic
  • Severity of Illness Index
  • Time Factors
  • United States
  • Young Adult